On Friday, H.C. Wainwright maintained a Buy rating on Protara Therapeutics (NASDAQ:TARA) with a steady price target of $23.00. According to InvestingPro data, analyst targets for TARA range from $14 to $50, with the stock currently trading at $6.02. The company has delivered impressive returns, with a 221% gain year-to-date and a remarkable 324% increase over the past year.
The endorsement follows Protara's recent presentation at the Society of Urologic Oncology (SUO) 2024 meeting on December 5, where the company updated on its Phase II ADVANCED-2 trial of TARA-002 in high-risk non-muscle invasive bladder cancer (HR-NMIBC), particularly noting strong early efficacy results.
The Phase II trial data highlighted by Protara showcased an 80% complete response rate (CRR) at any time for patients with carcinoma in situ (CIS) who were unresponsive to the Bacillus Calmette-Guerin (BCG) treatment, and an impressive 100% CRR at 6 months for this group.
With a market capitalization of $124 million, InvestingPro analysis shows the company maintains a strong financial position with more cash than debt and a healthy current ratio of 9.85x. The analyst pointed out that these results significantly exceed the typical 30-50% CRR benchmark for such patients, though the small patient cohort size was noted.
In addition to the promising results in BCG-unresponsive patients, TARA-002 also showed a 67% CRR at any time and 64% at 6 months in BCG-naïve patients. The overall CRRs stood at 70% at any time and 72% at 6 months across all patients. These outcomes were favorable when compared to approved therapies and investigational agents, which generally show a 37%-64% CRR at the 6-month mark.
The analyst from H.C. Wainwright addressed investor queries regarding the better response in BCG-unresponsive patients compared to BCG-naïve patients, suggesting that prior BCG exposure could prime the immune system, enhancing its response to TARA-002. The immune system's reaction might be influenced by different cytokine profiles induced by BCG and TARA-002, potentially contributing to the observed unique efficacy post-BCG exposure.
The firm reiterated its Buy rating and $23 price target for Protara Therapeutics, signaling confidence in the company's ongoing clinical developments and the potential of TARA-002 to offer an effective treatment option for patients with HR-NMIBC. InvestingPro data reveals the company maintains a "Good" overall financial health score of 2.56, despite currently not being profitable. Subscribers can access 14 additional ProTips and comprehensive financial metrics to better evaluate TARA's investment potential.
In other recent news, Protera Therapeutics has been making significant strides with its clinical trials. The company's Phase II ADVANCED-2 trial for TARA-002 in non-muscle invasive bladder cancer (NMIBC) achieved an 80% complete response rate at any time point and a 100% complete response rate at six months within a specific patient cohort. This surpasses the efficacy benchmark of 30-50% at six months, typically considered before proceeding to cystectomy.
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Protera's investigational therapy, Intravenous (IV) Choline Chloride, aimed at treating patients requiring parenteral support. This development underscores the urgency of addressing choline deficiency in these patients, which can lead to severe health issues.
Analyst firms Oppenheimer and TD Cowen have maintained positive ratings on Protera shares, following these promising developments. Oppenheimer upheld an Outperform rating, whereas TD Cowen retained its Buy rating, reflecting strong confidence in the company's potential. These ratings are based on the recent developments and the promising results from Protera's clinical trials.
Lastly, Protera Therapeutics has reported positive results from its LM registrational trial, where two out of three patients showed a complete response after a single dose of TARA-002. This development, along with the positive results from the ADVANCED-2 trial, underscores the potential of Protera's investigational therapies in addressing unmet medical needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.